I'm staying invested here as well!
(RTTNews) - Corcept Therapeutics Inc. (CORT) reported a rise in earnings for the second quarter on Wednesday, as revenue increased by over 30%, reflecting strong sales of Cushing's syndrome treatments and the launch of Lifyorli. The company has raised its revenue forecast for the full year 2026.
Net income for the quarter rose to $43.0 million, or $0.36 per share, from $35.1 million, or $0.29 per share, in the prior-year period.
Revenue in the second quarter rose 32% to $256.1 million, compared with $194.4 million in the prior year. Revenue included $208.6 million from Korlym and its approved generic, as well as $47.6 million from Lifyorli, which was launched following its FDA approval in March 2026.
Corcept raised its revenue forecast for 2026 from $950 million to $1.1 to $1.2 billion, citing the continued strength of its oncology and Cushing’s syndromebusiness segments.
